IMPAACT P1089 (VERSION 10) A LABORATORY STUDY TO ASSESS THE IMMUNOGENICITY

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 2009年H1N1甲型流感病毒在美国的持续流行传播很可能在秋冬季节大大增加，届时社会交往和气候条件更有利于流感病毒的传播。 虽然迄今为止的报告表明，健康的个体通常患有轻微疾病，但包括免疫缺陷在内的潜在医疗条件似乎会增加患严重疾病的风险，甚至会因H1N1大流行而死亡。 因此，了解几种已获许可的甲型H1N1流感2009单价疫苗在围产期感染HIV-1的儿童和青少年中的免疫原性，对于满足这一脆弱人群的卫生保健需求至关重要。 众所周知，季节性流感感染在成年人群中广泛传播之前会影响社区中的儿童。 对于2009年H1N1甲型流感病毒，年轻人群对疾病的易感性似乎更加明显，因为三分之一的老年人具有可测量的血清HAI或针对2009年H1N1甲型流感病毒的中和抗体水平，而年轻人和儿童完全缺乏保护滴度。血清学数据与观察结果一致，即病毒的发病率和疾病严重程度似乎在50岁以下的相对保护的年轻人群中要高得多。 目前正在努力评估甲型H1N1流感2009单价疫苗在健康儿童以及其他人群中的作用。 保护HIV-1围产期感染的儿童和青少年免受2009 H1N1甲型流感病毒的侵害需要了解这些新许可产品在该人群中的免疫原性。 本研究P1089将评估美国和波多黎各围产期感染HIV-1的儿童和青少年接受许可的甲型H1N1流感2009单价疫苗后的免疫应答。 为了了解疾病和保护机制，我们将调查该人群的短期血清应答。 总之，2009年H1N1甲型流感病毒很可能感染相当大比例的围产期感染HIV-1的儿童和青少年。 必须在HIV-1围产期感染儿童中确定获得许可的甲型H1N1流感2009单价疫苗的免疫原性，以确保该人群得到保护。 缺乏保护性免疫反应将支持采取额外措施保护这一高风险人群的必要性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. It is very likely that the continuing epidemic spread of 2009 H1N1 Influenza A virus infection in the US will greatly increase in the fall-winter season when social interactions and climactic conditions become even more conducive to spread of influenza viruses. While reports to date suggest that healthy individuals typically have a mild illness, underlying medical conditions including immunodeficiency appear to increase risk for severe disease and even death with pandemic H1N1. Thus, knowledge of the immunogenicity of several of the licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-1 perinatally infected children and youth is critically important to address the health care needs of this vulnerable population. It is well established that seasonal influenza infection impacts children in a community before becoming widespread in adult populations. Susceptibility to disease among young populations appears even more pronounced with 2009 H1N1 Influenza A virus as one third of older adults have measurable levels of serum HAI or neutralizing antibody against the 2009 H1N1 Influenza A virus while young adults and children completely lack protective titers. The serologic data is consistent with the observation that the attack rate and disease severity for the virus appears to be much higher in younger populations with relative protection of those 50 years of age. Efforts are currently underway to evaluate Influenza A (H1N1) 2009 monovalent vaccines in healthy children as well as other populations. Protection of HIV-1 perinatally infected children and youth from 2009 H1N1 Influenza A virus will require knowledge of immunogenicity of these new licensed products in this population. This study, P1089, will assess the immune response following receipt of licensed Influenza A (H1N1) 2009 monovalent vaccines in HIV-1 perinatally infected children and youth in the US and Puerto Rico. In order to understand the mechanism of disease and protection, we will investigate the short term seroresponse in this population. In summary, 2009 H1N1 Influenza A virus is likely to infect a significant proportion of HIV-1 perinatally infected children and youth. Immunogenicity of licensed available Influenza A (H1N1) 2009 monovalent vaccines must be established in HIV-1 perinatally infected children in order to assure that this population is protected. Lack of a protective immune response would support the need for additional measures to protect this high risk population.